EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form

Keyword(s):

Human Metabolites

Molecule Category

Free-form


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	FGBPLWBOJNYWTG-UHFFFAOYSA-N
Smiles	N#CC(C#N)=CC1=CC=C(C=C1C)N(CC)CCOC=2C=CC=CC2C3CCCCC3
InChI	InChI=1/C27H31N3O/c1-3-30(25-14-13-24(21(2)17-25)18-22(19-28)20-29)15-16-31-27-12-8-7-11-26(27)23-9-5-4-6-10-23/h7-8,11-14,17-18,23H,3-6,9-10,15-16H2,1-2H3

InChI Key

FGBPLWBOJNYWTG-UHFFFAOYSA-N

Smiles

N#CC(C#N)=CC1=CC=C(C=C1C)N(CC)CCOC=2C=CC=CC2C3CCCCC3

InChI

InChI=1/C27H31N3O/c1-3-30(25-14-13-24(21(2)17-25)18-22(19-28)20-29)15-16-31-27-12-8-7-11-26(27)23-9-5-4-6-10-23/h7-8,11-14,17-18,23H,3-6,9-10,15-16H2,1-2H3

Property Name	Value
Molecular Formula	C27H31N3O
Molecular Weight	413.25
AlogP	6.38
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	60.05
Molecular species	None
Aromatic Rings	2.0
Heavy Atoms	31.0

Property Name

Value

Molecular Formula

C27H31N3O

Molecular Weight

413.25

AlogP

6.38

Hydrogen Bond Acceptor

4.0

Hydrogen Bond Donor

0.0

Number of Rotational Bond

8.0

Polar Surface Area

60.05

Molecular species

None

Aromatic Rings

2.0

Heavy Atoms

31.0

Resources	Reference
CAS NUMBER	54079-60-6
NORMAN SUSDAT
PubChem	104688

Resources

Reference

CAS NUMBER

54079-60-6

NORMAN SUSDAT

PubChem

104688


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

[[4-[[2-(2-CYCLOHEXYLPHENOXY)ETHYL]ETHYLAMINO]-2-METHYLPHENYL]METHYLENE]MALONONITRILE

Structure

Physicochemical Descriptors

Cross References